ChemoCentryx Cancels IPO

ChemoCentryx Inc., a Mountain View, Calif.-based developer of oral drugs for autoimmune diseases, inflammatory diseases and oncology, has withdrawn registration for a $57.5 million IPO, citing “market conditions.” The company had planned to trade on the Nasdaq, with Credit Suisse serving as lead underwriter.

ChemoCentryx recently raised $50 million from existing investor GlaxoSmithKline, at a higher valuation than on its Series D round in March 2007 ($30m round at a $188m post-money). Overall, the company has raised around $155 million from GSK, OrbiMed Advisors, HBM BioVentures, Alta Partners, HealthCap and GIMV.

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.